Clinical trials: Pheochromocytoma/Paraganglioma
Adrenocortical Carcinoma, Pheochromocytoma
A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
This is a multicenter, Phase 1/2, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.
- Conditions
- Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma
- Trial name
- Spencer (NCT04187404)
- Testing
- EO2401, Nivolumab
- Where
- 12 sites in United States, Denmark and 6 more
- Volunteers
- 70 people
- Sponsor
- Enterome
Pheochromocytoma, Paraganglioma
In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma
This study will enroll up to 30 evaluable patients with pheochromocytoma or paraganglioma who are undergoing surgical or systemic treatment.
- Trial name
- NCT05636540
- Testing
- [18F]FluorThanatrace ([18F]FTT)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Heather Wachtel
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC)
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Background: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types.
- Conditions
- Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC), Mesothelioma, Pheochromocytoma/Paraganglioma (PPGL)
- Trial name
- NCT06503146
- Testing
- [18F]FAPI-74, [18F]FDG
- Where
- United States
- Volunteers
- 320 people
- Sponsor
- National Cancer Institute (NCI)
Pheochromocytoma, Paraganglioma
Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
The purpose of this sub-study is to provide expanded access of AZEDRA (Ultratrace Iobenguane I 131) and to evaluate the safety and tolerability of AZEDRA in subjects with iobenguane-avid malignant and/or recurrent…
- Trial name
- NCT02961491
- Testing
- Ultratrace Iobenguane I131
- Where
- 3 sites in United States
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Cushing Syndrome, Aldosteronism
China Adrenal Disease Registry
Epidemiologic studies have revealed a tremendous increase in the prevalence of adrenal associated disease and related mortality worldwide.
- Conditions
- Cushing Syndrome, Aldosteronism, Hypoadrenalism, Congenital Adrenal Hyperplasia
- Trial name
- CASE (NCT04890444)
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Pheochromocytoma, Endocrine Disease
Diagnosis of Pheochromocytoma
The goal of this study is to develop better methods of diagnosis, localization, and treatment for pheochromocytomas. These tumors, which usually arise from the adrenal glands, are often difficult to detect with current methods.
- Conditions
- Pheochromocytoma, Endocrine Disease, Endocrine Diseases
- Trial name
- NCT00004847
- Testing
- ([18F]-DOPA), ([18F]-6F-DA)
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Pheochromocytoma, Paraganglioma
Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma
Primary Objective: To determine the response rate (RR) of metastatic or locally advanced pheochromocytoma/paraganglioma to axitinib administered daily. Secondary Objectives: Determine the progression-free survival.
- Trial name
- NCT03839498
- Testing
- Axitinib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
Adrenal Gland Pheochromocytoma, Carcinoma In Situ
Project: Every Child for Younger Patients With Cancer
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and…
- Conditions
- Adrenal Gland Pheochromocytoma, Carcinoma In Situ, Central Nervous System Neoplasm, Childhood Immature Teratoma
- Trial name
- NCT02402244
- Testing
- Cytology Specimen Collection Procedure, Medical Chart Review
- Where
- 279 sites in United States, Australia and 4 more
- Volunteers
- 75,000 people
- Sponsor
- Children's Oncology Group
Recurrent Neuroendocrine Tumor, Metastatic Neuroendocrine Tumor
Phase 2 Study of ONC201 in Neuroendocrine Tumors
The purpose of this study is to learn if a new drug, ONC201 can make tumors become smaller or go away completely. Investigators also want to learn if ONC201 can prevent new deposits of cancer from appearing in new places in…
- Trial name
- NCT03034200
- Testing
- ONC201
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Peter Anderson
Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma
Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.
Determine the safety and effectiveness of Lu-177 DOTATOC in adult subjects with somatostatin receptor-expressing Pulmonary, Pheochromocytoma, Paraganglioma, Unknown primary, and Thymus neuroendocrine tumors or any other…
- Conditions
- Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma, Paraganglioma, Thymus Carcinoid
- Trial name
- PUTNET (NCT04276597)
- Testing
- 177Lu-DOTATOC
- Where
- United States
- Sponsor
- Excel Diagnostics and Nuclear Oncology Center
Neuroendocrine Tumors
Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression
This is a non-randomized phase II , open label, comparative study. Patients with advanced non-resectable and/or progressive gastro-entero-pancreatic Neuroendocrine Tumours - GEP-NET, (G1, G2 and G3), Broncho-pulmonary Carcinoids…
- Trial name
- POLNETS_PRRT (NCT04029428)
- Testing
- 90Y-DOTATATE, (177Lu-DOTAOTyr3)Octreotate, 90Y DOTATATE and 177Lu DOTATATE (mix each of 50%)
- Where
- Poland
- Volunteers
- 150 people
- Sponsor
- University of Warmia and Mazury
Von Hippel-Lindau Disease, Hemangioblastoma
Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
Von Hippel Lindau disease (VHLD) is an inherited syndrome characterized by vascular malformations, kidney cancer, adrenal gland and pancreas tumors.
- Conditions
- Von Hippel-Lindau Disease, Hemangioblastoma, Renal Cell Carcinoma, Pheochromocytoma
- Trial name
- VHLimage (NCT00970970)
- Testing
- 89Zr bevacizumab PET scan
- Where
- Netherlands
- Volunteers
- 22 people
- Sponsor
- University Medical Center Groningen
Adrenocortical Carcinoma, Brain and Central Nervous System Tumors
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as cisplatin and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells.
- Conditions
- Adrenocortical Carcinoma, Brain and Central Nervous System Tumors, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00002608
- Testing
- cisplatin, doxorubicin hydrochloride, tamoxifen citrate
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Ottawa Regional Cancer Centre
Adrenal Disease
Comparison Between Posterior Retroperitoneoscopic Adrenalectomy and Laparoscopic Adrenalectomy
The purpose of this study is to compare two surgical methods of adrenalectomy. One is called PRA(posterior retroperitoneal adrenalectomy), which is performed through 3 or 4 holes at patient's back.
- Trial name
- PRA (NCT01676025)
- Testing
- PRA, LA
- Where
- South Korea
- Volunteers
- 83 people
- Sponsor
- Seoul National University Hospital
Acute Leukemia, Adenomatous Polyposis
Familial Investigations of Childhood Cancer Predisposition
NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll.
- Conditions
- Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML
- Trial name
- SJFAMILY (NCT03050268)
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- St. Jude Children's Research Hospital
PGL
Prediction of Myocardial Injury After Laparoscopic Pheochromocytoma/ParaGangLioma Resection
This observational study was conducted in patients undergoing elective laparoscopic pheochromocytoma/paraganglioma(PPGL) resection. It mainly answers the following two main questions: 1.
- Trial name
- MI-PPGL (NCT05752773)
- Where
- China
- Volunteers
- 700 people
- Sponsor
- Peking Union Medical College Hospital
Pheochromocytoma, Paraganglioma
Cardiac and Vascular Changes in Pheochromocytoma and Paraganglioma
PHEOCHROMOCYTOMA (PCC)/ PARAGANGLIOMA are catecholamine secreting tumors with varied manifestations. Besides hypertension, PCC patients may have subclinical to overt cardiac and vascular dysfunction, which are important to…
- Conditions
- Pheochromocytoma, Paraganglioma, Cardiovascular Morbidity
- Trial name
- PheoCard (NCT05082311)
- Testing
- Observational study
- Where
- India
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
Risk Grading System, Pheochromocytoma and Paraganglioma (PPGL)
The IUPU-PPGL Score: A Imaging-Based Tool for Stratifying Surgical Complexity in Patients With Pheochromocytoma and Paragangliom（PPGL）
This study aimed to develop the imaging-based IUPU-PPGL score and evaluate its ability to stratify surgical complexity and its association with perioperative outcomes.
- Conditions
- Risk Grading System, Pheochromocytoma and Paraganglioma (PPGL), Quantitative Assessment
- Trial name
- NCT07412158
- Testing
- observational diagnostic model development
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Peking University First Hospital
Pheochromocytoma
Diagnosis and Treatment of Pheochromocytoma
Pheochromocytoma is a tumor of the adrenal gland. This tumor is typically benign (not cancerous) and can be cured by surgical removal.
- Trial name
- NCT00001229
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)